Congressional Report Details Limits of Trump Administration’s Marijuana Rescheduling for Industry and Patients

A recent report from the Congressional Research Service (CRS) has clarified the immediate and long-term consequences of the Trump administration’s decision to reschedule medical marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). While the move offers new legal protections for certified medical cannabis patients who obtain their products from state-licensed dispensaries, the broader cannabis industry remains in a gray area, especially when it comes to recreational marijuana. According to the report, the industry is not “immediately” brought into full compliance with federal law, and significant regulatory hurdles remain, particularly for non-medical cannabis businesses

The Justice Department’s final order, which initiated the rescheduling, also instructed the Drug Enforcement Administration (DEA) to create expedited registration procedures for state medical marijuana license holders. In response, the DEA has launched an online application process for medical cannabis businesses seeking federal recognition. However, as the CRS points out, “marijuana is not” considered a pharmaceutical controlled substance by prescription drug standards, meaning that most cannabis products still cannot be dispensed via a standard prescription. The report notes, “the order appears to authorize end users to possess marijuana for medical use without a CSA-compliant prescription,” but stops short of granting full legal clarity to industry participants

The CRS analysis further explains that while the scheduling change could allow some manufacturers, distributors, and dispensers of medical marijuana to comply with the CSA, it does not protect businesses from other federal liabilities. The Federal Food, Drug, and Cosmetic (FD&C) Act still prohibits the introduction of unapproved drugs into interstate commerce, and marijuana itself has not received FDA approval. As a result, cannabis companies—even those operating within state laws—could still face criminal penalties. This legal uncertainty is amplified for recreational cannabis, which remains excluded from the rescheduling action and would remain federally illegal even if broader scheduling changes occur in the future

Despite these limitations, the CRS report highlights two major benefits of the rescheduling for the medical cannabis sector: a reduction in research barriers and the ability for state-licensed cannabis businesses to claim federal tax deductions under IRS code 280E. “Because the provision applies only to activities involving substances in Schedule I or II, to the extent marijuana is moved from Schedule I to Schedule III, marijuana businesses can deduct business expenses on federal tax filings,” the CRS stated. The Treasury Department and IRS have announced plans to release new tax guidance for the industry in light of this change

Political reactions to the rescheduling have been mixed. President Trump emphasized the medical benefits of cannabis, stating, “A lot of people are suffering from big problems, which this seems to be the best answer. They’re very happy about it. So the rescheduling is starting, and that’s a big thing, rescheduling.” Meanwhile, the White House Office of National Drug Control Policy (ONDCP) has expressed concerns about high-potency marijuana and the exploitation of state legalization laws by criminal groups. There is also ongoing debate about federal restrictions on hemp-derived THC products, with the administration sending mixed signals about future policy directions

From the OG Lab newsroom perspective, the CRS report underscores the complexity of federal cannabis reform and the persistent legal ambiguities facing both medical and recreational operators. While the move to Schedule III marks a significant policy shift and provides tangible benefits to some segments of the industry, uncertainty remains around enforcement, taxation, and future regulatory actions. Stakeholders across the cannabis ecosystem should closely monitor upcoming federal hearings and tax rule changes, as the long-term impact of rescheduling will depend on how these unresolved issues are addressed